Breast Cancer Diagnostics Market Size and Forecast 2024-2033|Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation

Unrecognizable nurse taking a mammogram exam to an adult patient at the hospital

Overview and Scope

Breast cancer is characterised by uncontrolled growth of cells in the breast, causing lumps. The breast cancer diagnostic devices are used to diagnose cancer that occurs in the breasts

Sizing and Forecast

The breast cancer diagnostics market size has grown strongly in recent years. It will grow from $4.42 billion in 2023 to $4.8 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to awareness and screening campaigns, mammography screening, technological advancements, genetic testing, multidisciplinary approach.

The breast cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $6.47 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to personalized medicine, liquid biopsies, 3d mammography (tomosynthesis), ai and machine learning, telemedicine and remote consultations. Major trends in the forecast period include advancements in imaging technologies, personalized medicine, liquid biopsies, ai and machine learning.

To access more details regarding this report, visit the link:

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Segmentation & Regional Insights

The breast cancer diagnostics market covered in this report is segmented

1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Other Types

2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Other Technologies

3) By Cancer Type: BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Other Cancer Types

4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies

5) By End Users: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

North America was the largest region in the breast cancer diagnostics market in 2023. Asia-Pacific was the second largest region in the breast cancer diagnostics industry. The regions covered in the breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Intrigued to explore the contents? Secure your hands-on sample copy of the report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3284&type=smp

Major Driver Impacting Market Growth

The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. For instance, in January 2022, according to the American Cancer Society, a US-based health organization that works for cancer elimination, Around 287,850 new instances of invasive breast cancer and 51,400 occurrences of DCIS are estimated to be diagnosed in women in the United States in 2022, with an anticipated 43,250 fatalities due to breast cancer .Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market.

Key Industry Players

Major companies operating in the breast cancer diagnostics market include Abbott Laboratories, Myriad Genetics Inc., Hologic Inc., Koninklijke Philips N.V., Fujifilm Holdings Corporation, GE Healthcare, Thermo Fisher Scientific Inc., Siemens AG, NanoString Technologies Inc., Gamma Medica Inc., Aurora Imaging Technology Inc., Dilon Technologies Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd, Micrima Limited, Provista Diagnostics Inc., Leica Biosystems Nussloch GmbH, bioTheranostics Inc., Bio-Rad Laboratories Inc., Illumina Inc., Biocept Inc., Epigenomics AG, AstraZeneca plc, Quest Diagnostics Incorporated, Agilent Technologies Inc., Cepheid, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Oncocyte Corporation, PerkinElmer Inc., Sysmex Corporation, Veracyte Inc.

The breast cancer diagnostics market report table of contents includes:

1. Executive Summary

2. Breast Cancer Diagnostics Market Characteristics

3. Breast Cancer Diagnostics Market Trends And Strategies

4. Breast Cancer Diagnostics Market – Macro Economic Scenario

5. Global Breast Cancer Diagnostics Market Size and Growth

26. South America Breast Cancer Diagnostics Market

27. Brazil Breast Cancer Diagnostics Market

28. Middle East Breast Cancer Diagnostics Market

29. Africa Breast Cancer Diagnostics Market

30. Breast Cancer Diagnostics Market Competitive Landscape And Company Profiles

Top Major Players: